Table 1.
Characteristics of the participants.
| Total (n = 197) | Training (n = 129) | Validation (n = 68) | P | |
|---|---|---|---|---|
| Participants | ||||
| Potential living donor | 125 (64.5) | 83 (64.3) | 42 (61.8) | 0.87 |
| Post-donor | 27 (13.7) | 18 (14.0) | 9 (13.2) | |
| Transplant recipient | 45 (22.8) | 28 (21.7) | 17 (25.0) | |
| Age, y | 60.1 ± 12.4 | 60.4 ± 12.7 | 59.5 ± 11.8 | 0.64 |
| Male | 84 (42.6) | 56 (43.4) | 22 (41.2) | 0.76 |
| Body mass index, kg/m2 | 23.2 ± 3.5 | 23.5 ± 3.7 | 22.6 ± 2.9 | 0.062 |
| Body surface area, m2 | 1.63 ± 0.18 | 1.64 ± 0.18 | 1.62 ± 0.19 | 0.50 |
| Diabetes | 10 (5.1) | 7 (5.4) | 3 (4.4) | 0.76 |
| Hypertension | 34 (17.3) | 22 (17.1) | 12 (17.7) | 0.92 |
| Hyperlipidemia | 35 (17.8) | 20 (15.5) | 15 (22.1) | 0.26 |
| Hemoglobin, g/dL | 12.7 ± 1.7 | 12.8 ± 1.6 | 12.5 ± 1.8 | 0.28 |
| Serum albumin, g/dL | 4.0 ± 0.3 | 4.0 ± 0.3 | 4.0 ± 0.3 | 0.94 |
| Serum creatinine, mg/dL | 0.86 ± 0.36 | 0.87 ± 0.37 | 0.85 ± 0.33 | 0.73 |
| Serum cystatin C, mg/L | 1.1 ± 0.4 | 1.1 ± 0.4 | 1.1 ± 0.4 | 0.56 |
| Plasma d-serine, μM | 2.3 ± 0.8 | 2.3 ± 0.8 | 2.3 ± 0.3 | 0.61 |
| Inulin clearance, mL/min/1.73 m2 | 66.7 ± 20.2 | 64.4 ± 20.5 | 67.2 ± 19.9 | 0.80 |
| Creatinine clearance, mL/min/1.73 m2 | 98.2 ± 30.1 | 98.0 ± 30.9 | 98.7 ± 28.7 | 0.87 |
| d-Serine clearance, mL/min/1.73 m2 | 55.7 ± 16.9 | 55.3 ± 17.2 | 56.4 ± 16.4 | 0.66 |
| eGFR_cre, mL/min/1.73 m2 | 67.5 ± 19.7 | 67.9 ± 20.8 | 66.8 ± 17.5 | 0.73 |
| eGFR_cys, mL/min/1.73 m2 | 71.1 ± 21.6 | 70.1 ± 21.9 | 72.8 ± 21.2 | 0.42 |
Data, n (%) or mean ± SD. eGFR_cre and eGFR_cys denote creatinine- and cystatin C-based estimated glomerular filtration rates (eGFRs), respectively, based on the Japanese formula2,18. P values were given for the difference between the training and validation cohorts.